Loading...
XNASNARI
Market cap4.64bUSD
Jan 08, Last price  
79.30USD
1D
-0.19%
1Q
95.18%
IPO
86.54%
Name

Inari Medical Inc

Chart & Performance

D1W1MN
XNAS:NARI chart
P/E
P/S
9.40
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
4.78%
Rev. gr., 5y
135.40%
Revenues
494m
+28.73%
6,829,00051,128,905139,670,000276,984,000383,471,000493,632,000
Net income
-2m
L-94.41%
-10,153,000-1,907,11813,789,0009,840,000-29,267,000-1,636,000
CFO
36m
P
-10,892,000-4,935,9021,912,00025,486,000-13,972,00035,927,000
Earnings
Feb 26, 2025

Profile

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
IPO date
May 22, 2020
Employees
1,100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
493,632
28.73%
383,471
38.45%
Cost of revenue
497,264
411,570
Unusual Expense (Income)
NOPBT
(3,632)
(28,099)
NOPBT Margin
Operating Taxes
5,882
3,082
Tax Rate
NOPAT
(9,514)
(31,181)
Net income
(1,636)
-94.41%
(29,267)
-397.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,921
177,138
BB yield
-0.27%
-5.27%
Debt
Debt current
3,384
1,311
Long-term debt
62,402
63,263
Deferred revenue
Other long-term liabilities
66,400
Net debt
(51,166)
(270,127)
Cash flow
Cash from operating activities
35,927
(13,972)
CAPEX
(4,710)
(9,951)
Cash from investing activities
(58,018)
(195,216)
Cash from financing activities
1,171
177,138
FCF
1,665
(56,413)
Balance
Cash
115,452
326,401
Long term investments
1,500
8,300
Excess cash
92,270
315,527
Stockholders' equity
(39,543)
(45,947)
Invested Capital
590,920
495,236
ROIC
ROCE
EV
Common stock shares outstanding
56,771
52,838
Price
64.92
2.14%
63.56
-30.36%
Market cap
3,685,551
9.74%
3,358,363
-33.81%
EV
3,634,385
3,088,236
EBITDA
7,103
(20,980)
EV/EBITDA
511.67
Interest
196
294
Interest/NOPBT